Citi Upgrades Bio-Techne to Buy from Neutral with $70 Price Target

Citi upgraded Bio-Techne (TECH) to Buy from Neutral with a price target of $70, up from $55. The firm views the company's growth and margin outlook as conservative, and believes the stock is undervalued at current levels. Easing tariffs, growth in China, and margin expansion are expected to drive upside to Bio-Techne's guidance.

Citi has upgraded Bio-Techne (TECH) to a "Buy" rating from "Neutral," with a new price target of $70, up from $55. The firm expects the company's growth and margin outlook to remain conservative, but believes the stock is undervalued at current levels. Easing tariffs, growth in China, and margin expansion are anticipated to drive upside to Bio-Techne's guidance [1].

The upgrade comes amidst a positive quarter for Bio-Techne, which reported better-than-expected fourth-quarter revenue and profit, driven by strong demand for its proteins, antibodies, and other research products [2]. The company also announced a strategic partnership with Spear Bio to distribute its next-generation immunoassays, further bolstering its growth prospects [3].

Citi's optimism is supported by recent market trends, with the S&P 500, NASDAQ Composite, and Russell 2000 Indices rebounding in the second quarter of 2025, driven by better-than-expected earnings and renewed optimism surrounding AI growth [4]. The technology sector, in particular, led the charge, with AI-related gains in semiconductors and strong performances from software and hardware companies [4].

However, investors should remain cautious, as trade tensions and geopolitical uncertainties continue to pose risks to the market [4]. Additionally, Bio-Techne's recent acquisition of Exosome Diagnostics Inc. and its ongoing divestiture of the business could introduce operational complexities [5].

References:
[1] https://stockanalysis.com/stocks/tech/
[2] https://seekingalpha.com/article/4814900-macquarie-mid-cap-growth-fund-q2-2025-commentary
[3] https://prnewswire.com/news-releases/bio-techne-corporation-and-spear-bio-announce-strategic-partnership-to-advance-therapeutic-development-with-ultrasensitive-biomarker-detection-301212074.html
[4] https://prnewswire.com/news-releases/bio-techne-corporation-technologies-utilized-in-recent-fda-approval-of-zevaskyn-cell-based-gene-therapy-301212074.html
[5] https://prnewswire.com/news-releases/bio-techne-announces-exosome-diagnostics-divestiture-301212074.html